Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parathyroid gland function in secondary hyperparathyroidism

I B Salusky1, W G Goodman

  • 1Department of Pediatrics, UCLA School of Medicine, USA.

Pediatric Nephrology (Berlin, Germany)
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.

Calcified tissue international·2015
Same author

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.

Journal of human hypertension·2015
Same author

Calcium-mediated parathyroid hormone suppression to assess progression of secondary hyperparathyroidism during treatment among incident dialysis patients.

The Journal of clinical endocrinology and metabolism·2013
Same author

[FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2011
Same author

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.

Clinical nephrology·2008
Same author

A new era in phosphate binder therapy: what are the options?

Kidney international. Supplement·2006
Same journal

Atypical renal phenotype with tubular proteinuria and hypercalciuria in siblings with nail-patella syndrome: evidence for a dual genetic diagnosis.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

Blood pressure control in pediatric hemodialysis: data from the SCOPE collaborative.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

Correlation between urinary soluble CD163 and endocapillary proliferation and fibrinoid necrosis in IgA vasculitis with nephritis.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

SGLT2i, anti-endothelin A and double endothelin and angiotensin inhibitors: a new future for chronic kidney disease in children.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

The role of urinary trehalase levels in the early diagnosis of acute kidney injury in dehydrated children.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

Neuron-specific enolase and brain-derived neurotrophic factor as developmental neurovascular markers in chronic kidney disease and kidney transplantation.

Pediatric nephrology (Berlin, Germany)·2026
See all related articles

Uremic patients do not have a higher set-point for parathyroid hormone release compared to healthy individuals. Calcitriol therapy impacts parathyroid gland function, but gland size and cell proliferation are key to secondary hyperparathyroidism severity.

Area of Science:

  • Nephrology
  • Endocrinology
  • Calcium Homeostasis

Background:

  • Parathyroid glands regulate calcium homeostasis via parathyroid hormone (PTH) release.
  • Secondary hyperparathyroidism in uremia is often associated with altered PTH set-point.
  • Previous methods for assessing PTH set-point may differ from established models.

Purpose of the Study:

  • To investigate the set-point for calcium-regulated PTH release in dialysis patients with secondary hyperparathyroidism.
  • To evaluate the effect of calcitriol therapy on parathyroid gland function.
  • To determine factors influencing the severity of secondary hyperparathyroidism.

Main Methods:

  • Dynamic testing of parathyroid glands using standardized calcium gluconate and sodium citrate infusions.

Related Experiment Videos

  • Comparison of set-point values between control subjects and dialysis patients.
  • Assessment of set-point values before and after calcitriol therapy.

    • Main Results:

    • No significant difference in set-point calcium-regulated PTH release was found between control and dialyzed patients (1.21 ± 0.04 vs. 1.24 ± 0.06 mmol/l).
    • Calcitriol therapy did not significantly alter the set-point (1.21 ± 0.01 vs. 1.22 ± 0.01 mmol/l).
    • Set-point did not differ across varying severities of secondary hyperparathyroidism.

    Conclusions:

    • The set-point for calcium-regulated PTH release is not elevated in dialysis patients with secondary hyperparathyroidism.
    • Calcitriol therapy influences parathyroid gland secretory capacity during hypocalcemia.
    • Parathyroid gland size and cell proliferation are critical determinants of secondary hyperparathyroidism severity.